Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses
Brief: Belite Bio Q2 Net Income USD -28.412 Million
Brief: Belite Bio Announces U.S. Food And Drug Administration Acceptance And Priority Review Of New Drug Application For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc expected to post a loss of 79 cents a share - Earnings Preview
Belite Bio, Inc expected to post a loss of 79 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Apollo, Phillips 66, Valero Energy
Belite Bio's Q1 net loss widens on higher R&D costs
Brief: Belite Bio Initiates Rolling Submission Of New Drug Application To The U.S. Food And Drug Administration For Tinlarebant For The Treatment Of Stargardt Disease
Belite Bio reports rise in Q4 preliminary net loss
Brief: Belite Bio FY Net Income USD -77.611 Million
U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth
Belite Bio climbs as BofA starts coverage with 'buy' rating
U.S. RESEARCH ROUNDUP-Crowdstrike, CSW Industrials, Targa Resources
U.S. STOCKS ON THE MOVE-CrowdStrike Holdings, Procter & Gamble, Ford Motor
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing
Belite Bio eyes fresh record after $350 mln equity raise